This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Opportunities Driving Adoption AI presents clear benefits for pharma marketers: 1. Misuse or insufficient anonymization can trigger HIPAA or GDPR violations. Documentation and Version Control : Keep detailed records of how AI content is created, reviewed, and approved. Is it legal to use AI to segment HCP audiences?
These include all licenses, previous disciplinary actions, and other supporting documents. HIPAA Notice of Privacy Practices: If you are considered a “covered entity” under federal law, your HIPAA Notice must be prominently placed on your customer-facing website. You should then prepare the materials you will need to apply.
Because the regulatory oversight of COVID became highly politicized, and after some missteps by FDA, some states have indicated that any federal decision will be reviewed, but that does not seem likely to present much a barrier in terms of timeline, if at all. In addition, the process of vaccination takes time.
The NHC encourages CMS to address barriers to access that prior authorization and other utilization management practices present for patients who need access to necessary prescription drugs. We also note this rule specifically does not apply to prescription drugs.
It also enhances the patient experience with easy-to-understand clinical trial information, such as a video about the Biobank study, as well as informed consent documents for electronic signature,” he continued. This was delivered through a patient-centric video about the Biobank study presented to the patient on an iPad, Lee explained.
We organize all of the trending information in your field so you don't have to. Join 11,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content